长春高新：注射用GenSci139境内生产药品临床试验获批

Group 1 - The core point of the article is that Changchun High-tech (000661) announced that its subsidiary, Changchun Jinsai Pharmaceutical Co., Ltd. (referred to as "Jinsai Pharmaceutical"), has received approval from the National Medical Products Administration for a clinical trial of GenSci139 injection in patients with advanced solid tumors [1] Group 2 - The approval allows Jinsai Pharmaceutical to conduct clinical trials, indicating progress in the development of GenSci139 as a potential treatment option [1]